Boston, MA (November 28, 2018) — Several ALS organizations announced on Wednesday that the first participant was successfully given a dose of AT-1501 in the first in-human trial of the potential treatment for ALS. AT-1501 was developed by the ALS Therapy Development Institute (ALS TDI), with support from The ALS Association, ALS ONE, and ALS Finding a Cure®, and is being brought into trials by Anelixis Therapeutics, Inc., a for-profit subsidiary of ALS TDI.
|
|
Scooped by
TEAM Mike Lopez Memorial Foundation |Find us on Twitter:@TEAMCUREALS
onto #ALS AWARENESS #LouGehrigsDisease #PARKINSONS November 29, 2018 3:32 AM
|
Your new post is loading...